Share this product Spiriva Respimat 2.5 Microgram Inhalation Solution Tiotrolium Re-usable

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe. 

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses. 

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Chronic obstructive pulmonary disease

Asthma: Add-on maintenance treatment

Safety Advice Warnings

Adverse effects (report/action)

• Drug induced bronchospasm may occur
• Prolonged treatment may lead to dental caries

Advice concerning formulation

• Not all available brands are recommended for all age groups
• Not all presentations are licensed for all indications

Advice on Administration

• Avoid contact with eyes

Advice on possible excipients

• Some formulations contain lactose

Discontinue due to test or exam

• Discontinue if paradoxical bronchospasm occurs

Patient Counselling

• Advise ability to drive/operate machinery may be affected by side effects
• Advise patient to report any blurred vision or any other eye symptoms
• Advise patient to report new or worsening signs of cardiac failure
• Asthma: Advise patients benefit of therapy is apparent after several doses
• Ensure patient has a fast acting bronchodilator available

Pre-treatment points to consider

• Not to be used as the sole or main treatment for severe or unstable asthma

Recommended monitoring

• Check patient is using correct inhaler technique
• Monitor closely patient at risk of cardiovascular disorders

Safety/advice in other condition

• Not to be used to relieve an acute asthmatic attack